Cargando…

A Randomized Multiple Dose Pharmacokinetic Study of a Novel PDE10A Inhibitor TAK-063 in Subjects with Stable Schizophrenia and Japanese Subjects and Modeling of Exposure Relationships to Adverse Events

BACKGROUND: Phosphodiesterase 10A (PDE10A) is selectively expressed in medium spiny neurons of the striatum. TAK-063 is a selective inhibitor of PDE10A in clinical development for the treatment of schizophrenia. OBJECTIVES: Safety, tolerability, and pharmacokinetics (PK) of TAK-063 were evaluated fo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Goldsmith, Paul, Affinito, John, McCue, Maggie, Tsai, Max, Roepcke, Stefan, Xie, Jinhui, Gertsik, Lev, Macek, Thomas A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2017
Materias:	Original Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5694427/ https://www.ncbi.nlm.nih.gov/pubmed/29103081 http://dx.doi.org/10.1007/s40268-017-0214-8

Ejemplares similares

A phase 1 study of the safety, tolerability, pharmacokinetics, and pharmacodynamics of TAK-063, a selective PDE10A inhibitor
por: Tsai, Max, et al.
Publicado: (2016)

A randomized, placebo-controlled, phase 1 study to evaluate the effects of TAK-063 on ketamine-induced changes in fMRI BOLD signal in healthy subjects
por: Yurgelun-Todd, Deborah A., et al.
Publicado: (2019)

Translational Development Strategies for TAK-063, a Phosphodiesterase 10A Inhibitor
por: Macek, Thomas A, et al.
Publicado: (2020)

Safety, tolerability, pharmacokinetics and pharmacodynamics of the anti‐CD38 cytolytic antibody TAK‐079 in healthy subjects
por: Fedyk, Eric R., et al.
Publicado: (2020)

Characterization of Binding and Inhibitory Properties of TAK-063, a Novel Phosphodiesterase 10A Inhibitor
por: Harada, Akina, et al.
Publicado: (2015)

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Rising TAK-438 (Vonoprazan) Doses in Healthy Male Japanese/non-Japanese Subjects
por: Sakurai, Yuuichi, et al.
Publicado: (2015)

S223. COMBINED TREATMENT WITH A SELECTIVE PDE10A INHIBITOR TAK-063 AND ANTIPSYCHOTICS AT SUBEFFECTIVE DOSES PRODUCES POTENT ANTIPSYCHOTIC-LIKE EFFECTS WITHOUT EXACERBATING SIDE EFFECTS PROFILE IN RODENTS
por: Suzuki, Kazunori, et al.
Publicado: (2018)

Population pharmacokinetic analysis of ulotaront in subjects with schizophrenia
por: Galluppi, Gerald R., et al.
Publicado: (2021)

A phase 1 study to evaluate the safety, tolerability and pharmacokinetics of TAK‐041 in healthy participants and patients with stable schizophrenia
por: Yin, Wei, et al.
Publicado: (2022)

Combined treatment with a selective PDE10A inhibitor TAK‐063 and either haloperidol or olanzapine at subeffective doses produces potent antipsychotic‐like effects without affecting plasma prolactin levels and cataleptic responses in rodents
por: Suzuki, Kazunori, et al.
Publicado: (2017)

Pharmacokinetic/Pharmacodynamic Modeling of the PDE4 Inhibitor TAK‐648 in Type 2 Diabetes: Early Translational Approaches for Human Dose Prediction
por: Plock, N, et al.
Publicado: (2017)

Pharmacokinetics and pharmacodynamics of the cytolytic anti‐CD38 human monoclonal antibody TAK‐079 in monkey – model assisted preparation for the first in human trial
por: Roepcke, Stefan, et al.
Publicado: (2018)

Safety, tolerability, pharmacokinetics, pharmacodynamics, bioavailability and food effect of single doses of soticlestat in healthy subjects
por: Wang, Shining, et al.
Publicado: (2021)

Bariatric Surgery and the Risk of Cerebrovascular Events: a Meta-analysis of 17 Studies Including 3,124,063 Subjects
por: Cai, Zixin, et al.
Publicado: (2022)

Pharmacokinetics and Safety of Defibrotide in Healthy Japanese Subjects
por: Umemura, Kazuo, et al.
Publicado: (2016)

Ataluren Pharmacokinetics in Healthy Japanese and Caucasian Subjects
por: Kong, Ronald, et al.
Publicado: (2019)

Pharmacokinetics of Imeglimin in Caucasian and Japanese Healthy Subjects
por: Fouqueray, Pascale, et al.
Publicado: (2022)

Multiple dose pharmacokinetics of inhaled loxapine in subjects on chronic, stable antipsychotic regimens
por: Spyker, Daniel A., et al.
Publicado: (2015)

Safety, pharmacokinetics and quantitative EEG modulation of TAK‐071, a novel muscarinic M1 receptor positive allosteric modulator, in healthy subjects
por: Yin, Wei, et al.
Publicado: (2021)

Alteration of a brain network with stable and strong functional connections in subjects with schizophrenia
por: Yuan, Liu, et al.
Publicado: (2022)

Evaluation of the Pharmacokinetics and Pharmacodynamics of Prasugrel in Japanese Elderly Subjects
por: Hasunuma, Tomoko, et al.
Publicado: (2017)

Comparative pharmacokinetics of maxacalcitol in healthy Taiwanese and Japanese subjects
por: Liu, Ming-Che, et al.
Publicado: (2020)

Pharmacokinetics and Pharmacodynamics of Ertugliflozin in Healthy Japanese and Western Subjects
por: Li, Yinhua, et al.
Publicado: (2021)

Application of Physiologically Based Pharmacokinetic Modeling to Predict Pharmacokinetics in Healthy Japanese Subjects
por: Matsumoto, Yuki, et al.
Publicado: (2018)

P063 Optogenetics for Obstructive Sleep Apnea
por: Knapman, F, et al.
Publicado: (2021)

Population Pharmacokinetics of Olanzapine and Samidorphan When Administered in Combination in Healthy Subjects and Patients With Schizophrenia
por: Sun, Lei, et al.
Publicado: (2021)

Population Pharmacokinetic Modeling and Exposure‐Response Analysis for Aripiprazole Once Monthly in Subjects With Schizophrenia
por: Wang, Xiaofeng, et al.
Publicado: (2022)

Pharmacokinetics and safety of a novel influenza treatment (baloxavir marboxil) in Korean subjects compared with Japanese subjects
por: Kim, Yun, et al.
Publicado: (2021)

Pharmacokinetic interactions of esaxerenone with amlodipine and digoxin in healthy Japanese subjects
por: Kirigaya, Yoshiaki, et al.
Publicado: (2020)

S43. A PROOF-OF-MECHANISM STUDY OF THE PDE10 INHIBITOR RG7203 IN PATIENTS WITH PROBING REWARD FUNCTIONS WITH IMAGING AND BEHAVIORAL APPROACHES
por: Umbricht, Daniel, et al.
Publicado: (2018)

Pharmacokinetics and pharmacodynamics of ticagrelor in subjects on hemodialysis and subjects with normal renal function
por: Teng, Renli, et al.
Publicado: (2018)

Randomised clinical trial: safety, tolerability, pharmacokinetics and pharmacodynamics of repeated doses of TAK-438 (vonoprazan), a novel potassium-competitive acid blocker, in healthy male subjects
por: Jenkins, H, et al.
Publicado: (2015)

O063. Moyamoya disease and headache: case report
por: Tozzi, Elisabetta, et al.
Publicado: (2015)

Comparison of the Safety, Tolerability, and Pharmacokinetics of Fidaxomicin in Healthy Japanese and Caucasian Subjects
por: Oshima, Hiroyuki, et al.
Publicado: (2015)

Pharmacokinetic characteristics of telaprevir in healthy Korean male subjects and comparisons with Japanese
por: Choi, Yewon, et al.
Publicado: (2018)

Pharmacokinetic Profiles of Ticagrelor Orodispersible Tablets in Healthy Western and Japanese Subjects
por: Teng, Renli, et al.
Publicado: (2017)

Pharmacokinetics (PK) and Safety of Intravenous (IV) Brincidofovir (BCV) in Healthy Adult Subjects
por: Wire, Mary Beth, et al.
Publicado: (2017)

Pharmacokinetics of Nintedanib in Subjects With Hepatic Impairment
por: Marzin, Kristell, et al.
Publicado: (2017)

Pharmacokinetics (PK) of Eravacycline in Subjects with Renal or Hepatic Impairment Compared with Healthy Subjects
por: Horn, Patrick, et al.
Publicado: (2017)

Population Pharmacokinetic Analysis of Rivipansel in Healthy Subjects and Subjects with Sickle Cell Disease
por: Nayak, Satyaprakash, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_50iulmfbaefmh4d6rfruee8v9q